Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
LMNX's Cash-to-Debt is ranked higher than
99% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. LMNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
LMNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.96  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
LMNX's Equity-to-Asset is ranked higher than
96% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. LMNX: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
LMNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.89 Max: 0.97
Current: 0.92
0.77
0.97
Interest Coverage No Debt
LMNX's Interest Coverage is ranked higher than
98% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. LMNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
LMNX' s Interest Coverage Range Over the Past 10 Years
Min: 5.66  Med: 77.41 Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 16.06
Beneish M-Score: -2.42
WACC vs ROIC
3.15%
5.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.13
LMNX's Operating Margin % is ranked higher than
59% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. LMNX: 8.13 )
Ranked among companies with meaningful Operating Margin % only.
LMNX' s Operating Margin % Range Over the Past 10 Years
Min: -23.22  Med: 7.85 Max: 15.72
Current: 8.13
-23.22
15.72
Net Margin % 5.00
LMNX's Net Margin % is ranked higher than
56% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. LMNX: 5.00 )
Ranked among companies with meaningful Net Margin % only.
LMNX' s Net Margin % Range Over the Past 10 Years
Min: -3.61  Med: 5.61 Max: 17.2
Current: 5
-3.61
17.2
ROE % 3.55
LMNX's ROE % is ranked lower than
53% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. LMNX: 3.55 )
Ranked among companies with meaningful ROE % only.
LMNX' s ROE % Range Over the Past 10 Years
Min: -3.44  Med: 4.22 Max: 13.24
Current: 3.55
-3.44
13.24
ROA % 3.28
LMNX's ROA % is ranked higher than
55% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. LMNX: 3.28 )
Ranked among companies with meaningful ROA % only.
LMNX' s ROA % Range Over the Past 10 Years
Min: -2.85  Med: 3.76 Max: 11.77
Current: 3.28
-2.85
11.77
ROC (Joel Greenblatt) % 21.13
LMNX's ROC (Joel Greenblatt) % is ranked higher than
67% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. LMNX: 21.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LMNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.68  Med: 22.71 Max: 40.65
Current: 21.13
-12.68
40.65
3-Year Revenue Growth Rate 7.40
LMNX's 3-Year Revenue Growth Rate is ranked higher than
63% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. LMNX: 7.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LMNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 20.15 Max: 194.3
Current: 7.4
4.8
194.3
3-Year EBITDA Growth Rate 12.30
LMNX's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. LMNX: 12.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LMNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: 8.1 Max: 45.3
Current: 12.3
-66.9
45.3
3-Year EPS without NRI Growth Rate 23.50
LMNX's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. LMNX: 23.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LMNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.7  Med: 8.7 Max: 104.9
Current: 23.5
-52.7
104.9
GuruFocus has detected 2 Warning Signs with Luminex Corp $LMNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LMNX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

LMNX Guru Trades in Q2 2016

Paul Tudor Jones 46,409 sh (+28.61%)
Jim Simons 1,002,900 sh (-0.49%)
Joel Greenblatt 11,923 sh (-81.07%)
» More
Q3 2016

LMNX Guru Trades in Q3 2016

Jim Simons 1,334,240 sh (+33.04%)
Joel Greenblatt Sold Out
Paul Tudor Jones 22,829 sh (-50.81%)
» More
Q4 2016

LMNX Guru Trades in Q4 2016

Paul Tudor Jones 28,352 sh (+24.19%)
Jim Simons 1,346,340 sh (+0.91%)
» More
Q1 2017

LMNX Guru Trades in Q1 2017

Ken Fisher 44,779 sh (New)
Paul Tudor Jones 35,347 sh (+24.67%)
Jim Simons 1,589,241 sh (+18.04%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 541711    SIC: 3841
Compare:NAS:OSUR, NAS:ATRI, NAS:IRTC, NAS:ATRC, NAS:NVCR, NAS:ANGO, NAS:LMAT, NAS:MLAB, AMEX:CRHM, NAS:PLSE, NYSE:GKOS, NAS:ELGX, NAS:ATRS, NAS:STAA, NAS:ENTL, NAS:NXTM, NAS:UTMD, NAS:DSCI, NAS:CFMS, NAS:SIEN » details
Traded in other countries:LMX.Germany,
Headquarter Location:USA
Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, & FLEXMAP 3D.

Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.

Ratios

vs
industry
vs
history
PE Ratio 63.78
LMNX's PE Ratio is ranked lower than
84% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. LMNX: 63.78 )
Ranked among companies with meaningful PE Ratio only.
LMNX' s PE Ratio Range Over the Past 10 Years
Min: 16.42  Med: 61.82 Max: 603.33
Current: 63.78
16.42
603.33
Forward PE Ratio 44.44
LMNX's Forward PE Ratio is ranked lower than
85% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. LMNX: 44.44 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 63.78
LMNX's PE Ratio without NRI is ranked lower than
83% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. LMNX: 63.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
LMNX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.42  Med: 61.82 Max: 603.33
Current: 63.78
16.42
603.33
Price-to-Owner-Earnings 69.42
LMNX's Price-to-Owner-Earnings is ranked lower than
60% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. LMNX: 69.42 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LMNX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.46  Med: 54.2 Max: 882
Current: 69.42
20.46
882
PB Ratio 2.19
LMNX's PB Ratio is ranked higher than
70% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. LMNX: 2.19 )
Ranked among companies with meaningful PB Ratio only.
LMNX' s PB Ratio Range Over the Past 10 Years
Min: 1.93  Med: 3.13 Max: 12.31
Current: 2.19
1.93
12.31
PS Ratio 3.08
LMNX's PS Ratio is ranked higher than
51% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. LMNX: 3.08 )
Ranked among companies with meaningful PS Ratio only.
LMNX' s PS Ratio Range Over the Past 10 Years
Min: 2.72  Med: 4.95 Max: 13
Current: 3.08
2.72
13
Price-to-Free-Cash-Flow 35.31
LMNX's Price-to-Free-Cash-Flow is ranked higher than
70% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. LMNX: 35.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LMNX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.38  Med: 55.85 Max: 588
Current: 35.31
18.38
588
Price-to-Operating-Cash-Flow 22.78
LMNX's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. LMNX: 22.78 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LMNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.8  Med: 29.67 Max: 306.61
Current: 22.78
11.8
306.61
EV-to-EBIT 37.11
LMNX's EV-to-EBIT is ranked lower than
78% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. LMNX: 37.11 )
Ranked among companies with meaningful EV-to-EBIT only.
LMNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -999.3  Med: 33.45 Max: 632.6
Current: 37.11
-999.3
632.6
EV-to-EBITDA 18.68
LMNX's EV-to-EBITDA is ranked higher than
58% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. LMNX: 18.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -154.8  Med: 24.95 Max: 4060.3
Current: 18.68
-154.8
4060.3
PEG Ratio 14.84
LMNX's PEG Ratio is ranked lower than
97% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. LMNX: 14.84 )
Ranked among companies with meaningful PEG Ratio only.
LMNX' s PEG Ratio Range Over the Past 10 Years
Min: 0.98  Med: 2.25 Max: 7.01
Current: 14.84
0.98
7.01
Shiller PE Ratio 52.82
LMNX's Shiller PE Ratio is ranked lower than
56% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. LMNX: 52.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
LMNX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 46.26  Med: 100.22 Max: 1224.5
Current: 52.82
46.26
1224.5
Current Ratio 5.79
LMNX's Current Ratio is ranked higher than
78% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. LMNX: 5.79 )
Ranked among companies with meaningful Current Ratio only.
LMNX' s Current Ratio Range Over the Past 10 Years
Min: 2.39  Med: 8.16 Max: 59.71
Current: 5.79
2.39
59.71
Quick Ratio 4.33
LMNX's Quick Ratio is ranked higher than
78% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. LMNX: 4.33 )
Ranked among companies with meaningful Quick Ratio only.
LMNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.86  Med: 7.11 Max: 58.8
Current: 4.33
1.86
58.8
Days Inventory 148.24
LMNX's Days Inventory is ranked lower than
65% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. LMNX: 148.24 )
Ranked among companies with meaningful Days Inventory only.
LMNX' s Days Inventory Range Over the Past 10 Years
Min: 69.92  Med: 155.77 Max: 182.42
Current: 148.24
69.92
182.42
Days Sales Outstanding 47.36
LMNX's Days Sales Outstanding is ranked higher than
86% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. LMNX: 47.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.52  Med: 49.25 Max: 66.89
Current: 47.36
38.52
66.89
Days Payable 33.94
LMNX's Days Payable is ranked lower than
52% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. LMNX: 33.94 )
Ranked among companies with meaningful Days Payable only.
LMNX' s Days Payable Range Over the Past 10 Years
Min: 36.85  Med: 52.92 Max: 78.2
Current: 33.94
36.85
78.2

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.29
LMNX's Dividend Yield % is ranked lower than
94% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. LMNX: 0.29 )
Ranked among companies with meaningful Dividend Yield % only.
LMNX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.29  Med: 0.33 Max: 0.33
Current: 0.29
0.29
0.33
Dividend Payout Ratio 0.19
LMNX's Dividend Payout Ratio is ranked lower than
99.99% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. LMNX: 0.19 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LMNX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.19
Forward Dividend Yield % 1.18
LMNX's Forward Dividend Yield % is ranked lower than
51% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. LMNX: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.29
LMNX's 5-Year Yield-on-Cost % is ranked lower than
92% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. LMNX: 0.29 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LMNX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.29  Med: 0.33 Max: 0.33
Current: 0.29
0.29
0.33
3-Year Average Share Buyback Ratio -1.30
LMNX's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. LMNX: -1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LMNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.8  Med: -2.55 Max: 0.4
Current: -1.3
-30.8
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.07
LMNX's Price-to-Net-Cash is ranked higher than
50% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. LMNX: 18.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LMNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.74  Med: 11.06 Max: 135.19
Current: 18.07
3.74
135.19
Price-to-Net-Current-Asset-Value 6.57
LMNX's Price-to-Net-Current-Asset-Value is ranked higher than
58% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. LMNX: 6.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LMNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.85  Med: 7.08 Max: 40.76
Current: 6.57
2.85
40.76
Price-to-Tangible-Book 3.71
LMNX's Price-to-Tangible-Book is ranked higher than
62% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. LMNX: 3.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LMNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.66  Med: 5.4 Max: 16.96
Current: 3.71
2.66
16.96
Price-to-Intrinsic-Value-Projected-FCF 1.49
LMNX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. LMNX: 1.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LMNX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.25  Med: 2.71 Max: 11.52
Current: 1.49
1.25
11.52
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.97
LMNX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
96% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. LMNX: 5.97 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.62
LMNX's Price-to-Median-PS-Value is ranked higher than
86% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. LMNX: 0.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LMNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.38 Max: 54.06
Current: 0.62
0.56
54.06
Price-to-Peter-Lynch-Fair-Value 6.76
LMNX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
90% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.21 vs. LMNX: 6.76 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LMNX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.19  Med: 3.13 Max: 25.89
Current: 6.76
1.19
25.89
Price-to-Graham-Number 3.24
LMNX's Price-to-Graham-Number is ranked lower than
59% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. LMNX: 3.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LMNX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52  Med: 3.62 Max: 16.53
Current: 3.24
1.52
16.53
Earnings Yield (Greenblatt) % 2.69
LMNX's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. LMNX: 2.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LMNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.6 Max: 6.7
Current: 2.69
0.2
6.7
Forward Rate of Return (Yacktman) % 12.12
LMNX's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. LMNX: 12.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LMNX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.3  Med: 1.1 Max: 30.1
Current: 12.12
-1.3
30.1

More Statistics

Revenue (TTM) (Mil) $285.4
EPS (TTM) $ 0.32
Beta0.15
Short Percentage of Float5.38%
52-Week Range $17.64 - 23.75
Shares Outstanding (Mil)43.94

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 307 299 294
EPS ($) 0.46 0.82 0.80
EPS without NRI ($) 0.46 0.82 0.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.24 0.28 0.32
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference May 25 2017 
Luminex Corporation Declares Second Quarter Cash Dividend May 24 2017 
Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay May 03 2017 
Luminex Corporation Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guida May 01 2017 
Luminex Corporation To Present At The Deutsche Bank 42nd Annual Health Care Conference Apr 26 2017 
Luminex Corporation To Present At Bank Of America Merrill Lynch 2017 Health Care Conference Apr 20 2017 
Luminex Corporation First Quarter Earnings Release Scheduled for May 1, 2017 Apr 10 2017 
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTA Jul 22 2015 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 

More From Other Websites
Henry Schein (HSIC) Rides on Global Growth, Strategic Deals May 26 2017
Patterson Companies (PDCO) Earnings Beat Estimates in Q4 May 26 2017
Veeva Systems (VEEV) Beats Q1 Earnings, Revenues Estimates May 26 2017
Stryker (SYK) at 52-Week High: What's Driving the Stock? May 26 2017
Quest Diagnostics Hits a 52-Week High on Solid Prospects May 26 2017
Align Technology Rises with Invisalign, SmartTrack Patents May 25 2017
Medtronic (MDT) Tops Q4 Earnings, Sales on Balanced Growth May 25 2017
Medtronic Puts First Patient in IN.PACT AV Access DCB Study May 25 2017
Boston Scientific (BSX) BT Study on Asthma Results Positive May 25 2017
Varian (VAR) ProBeam Proton Therapy System Now in Thailand May 25 2017
Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference May 25 2017
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan... May 24 2017
LabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk May 24 2017
Integra LifeSciences to Offer aap's LOQTEQ System in the US May 24 2017
Luminex Corporation Declares Second Quarter Cash Dividend May 24 2017
Quality Systems Professional Service a Drag, Competition Rife May 24 2017
Envision (EVHC) Acquires Gwinnett Emergency Specialists May 23 2017
Halyard Health (HYH) Expands CORGRIP System Product Line May 23 2017
Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes May 23 2017
IDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects May 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)